Deals
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Homology Medicines has raised $144 million in an initial public offering of stock.
Shire stock prices jumped up to 26 percent on rumors that Takeda Pharmaceuticals was considering a buyout.
GlaxoSmithKline walked away from a potential deal to acquire Pfizer’s consumer health unit four days ago and instead opted to acquire the stake controlled by Novartis. The deal will give GSK 100 percent ownership of the business unit.
For the second time Ablynx’s anti-IL-6R Nanobody, vobarilizumab has failed to pass muster. This morning Belgium-based company said vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.
Akebia Therapeutics, a kidney disease company, announced plans to offer and sell about $85 million of its common stock in an underwritten public offering.
GlaxoSmithKline has decided not to make a play for Pfizer’s consumer health business. The decision came one day after another potential suitor walked away from a potential deal.
Now that Reckitt Benckiser has walked away from a deal, GlaxoSmithKline is now the favorite to acquire Pfizer’s consumer health business.
Alzheon hopes to raise about $80 million, which will help fund two Phase III clinical trials for its ALZ-801 for Alzheimer’s disease.
Platinum Equity submitted a binding offer to Johnson & Johnson to buy LifeScan for $2.1 billion.
Lunbeck is acquiring Prexton Therapeutics BV, a 2012 spinout from Merck KgaA, and its Phase II treatment for Parkinson’s disease.